Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

A woman's hands star in a Lilly spot, shown playing key role in activities like gardening -- and discovering a lump in her ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...